NRX Pharmaceuticals
NRXP
47 hedge funds and large institutions have $47.6M invested in NRX Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 17 increasing their positions, 4 reducing their positions, and 5 closing their positions.
820% more call options, than puts
Call options by funds: $3.58M | Put options by funds: $389K
325% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 4
280% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 5
259% more capital invested
Capital invested by funds: $13.2M → $47.6M (+$34.3M)
42% more funds holding
Funds holding: 33 → 47 (+14)
13.36% more ownership
Funds ownership: 18.77% → 32.13% (+13%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BGI
B Group Inc
Dallas,
Texas
|
+$3.61M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
+$3.07M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$2.95M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$2.25M |
| 5 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$1.51M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$199K |
| 2 |
HT
Headlands Technologies
Chicago,
Illinois
|
-$83.9K |
| 3 |
AC
AXQ Capital
Jersey City,
New Jersey
|
-$70.7K |
| 4 |
VF
Virtu Financial
New York
|
-$50.1K |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
-$42.3K |
NRXP Hedge Fund Activity: Q2 2026 in Review
47 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in NRX Pharmaceuticals (NRXP) for Q2 2026, worth a combined $47.6M — up 259% from $13.2M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new NRXP positions and 5 closed out — a net gain of 14 holders — while 17 added to existing stakes and 4 trimmed.
The largest buyer was B Group Inc, adding an estimated $3.61M. The largest seller was XTX Topco, cutting an estimated $199K.
- 47 institutional investors held NRX Pharmaceuticals (NRXP) as of Q2 2026, up from 33 in Q1 2026.
- Funds reported $47.6M of NRX Pharmaceuticals stock for Q2 2026, up 259% quarter-over-quarter.
- 19 funds opened new NRX Pharmaceuticals positions in Q2 2026 and 5 closed out, a net change of +14 holders.
- The largest NRX Pharmaceuticals buyer in Q2 2026 was B Group Inc, an estimated $3.61M added.
- The largest NRX Pharmaceuticals seller in Q2 2026 was XTX Topco, an estimated $199K sold.
Based on aggregated 13F filings for Q2 2026.